On October 23, 2025, Dr. Zhiming (Tiffany) Jiang, General Manager of Wantai Group, and Dr. Huirong (Harry) Pan,General Manager of Xiamen Innovax Biotech Co., Ltd. (“Innovax”), participated in the 37th International Papillomavirus Society (IPVS) Conference in Bangkok, Thailand. They chaired a dedicated symposium titled “A New Era of HPV Vaccines: The Efforts from Developing Country Manufacturers for Global Cervical Cancer Elimination,” which attracted significant attention and sparked lively discussions among attending experts and scholars. Meanwhile, under the theme “Together Against HPV,” Innovax’s booth (#09) also drew considerable interest, engaging a steady stream of scholars and potential partners in active exchanges.

The symposium served as a core academic event of Innovax’s participation. It was chaired by the renowned Dr. Wichai Termrungruanglert, Vice President of the Royal Thai College of Obstetricians. During the session, INNOVAX and Xiamen University jointly presented “Improving Global Equity in HPV Prevention: The Promise of a Novel E. coli-Expressed 9-Valent Vaccine.” Professor Ting Wu from Xiamen University presented, for the first time to the international academic community, three-year follow-up data¹ from a head-to-head clinical trial comparing Cecolin 9 with a marketed HPV 9-valent vaccine. The clinical results demonstrate that there are comparable immunogenicity and safety profiles between Cecolin 9 and the marketed HPV 9-valent vaccine, underscoring its significant potential to improve equity in global HPV prevention.

This was followed by a presentation on “Together Against HPV: Leveraging Strong Partnerships for Cecolin 9 Local Production and Equitable Access in Thailand” by Dr. Nakorn Premsri, Director of the National Vaccine Institute of Thailand (NVI) and Dr. Boonrak Thawornrungroaj, Managing Director of Global Biotech Products Co., Ltd. (GBP). They detailed the localization strategy and implementation progress for Cecolin 9 in Thailand², highlighting the crucial role of international collaboration in enhancing stable vaccine supply and accessibility within the region.

The symposium was honored to host representatives from the Gates Foundation (GF), the Clinton Health Access Initiative (CHAI), Program for Appropriate Technology in Health (PATH), International Vaccine Institute (IVI) and experts from industries, etc.. Attendees spoke highly of Innovax’s significant contributions to advancing the global elimination of cervical cancer and expressed strong commitment to further strengthen collaboration, working together to advance the global cervical cancer elimination.

References:
1.Zhong GH, Bi ZH, Chu K, et al. Immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil9 in Chinese women aged 18–26 years: three-year follow-up data from a randomised clinical trial. The Lancet Regional Health - Western Pacific. 2025 Sep. 62: 101671. https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(25)00210-X/fulltext
2.Cecolin 9 is APPROVED by China NMPA and not currently available for sale or marketing in Thailand.

About the International Papillomavirus Society (IPVS):

Since its foundation, the purpose of the International Papillomavirus Society (IPVS) has been to promote worldwide exchange of ideas, knowledge, and research materials among basic, clinical and public health research professionals concerned with human and animal papillomaviruses and their associated diseases. IPVS also strives to facilitate research, and to promote the translation of research results into new clinical applications and public health policies. IPVS serves as the organizational structure for the field of biomedical scientists, physicians and other health care providers engaged in all manner of papillomavirus research.

About Xiamen Innovax Biotech Co., Ltd. (INNOVAX):

As one of the leading vaccine manufacturers in China, Xiamen Innovax Biotech Co., Ltd. (INNOVAX) was founded in 2005 and has been dedicated to human vaccine development, manufacturing and commercialization for nearly 20 years. As a wholly owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Wantai BioPharm), a public listed company in China (Stock Code: 603392), INNOVAX’s mission is to provide high-quality and affordable vaccines to improve human well-being.

INNOVAX has developed a unique recombinant virus-like particle (VLP) vaccine platform based on Escherichia coli, leveraging this cutting-edge technology to successfully launch the world’s first recombinant hepatitis E vaccine (Hecolin) and the world’s second HPV bivalent vaccine (Cecolin). In 2025, INNOVAX’s HPV 9-valent vaccine (Cecolin 9) was approved in China, which is the world’s second HPV 9-valent vaccine. INNOVAX is committed to advancing in innovation for life.

For more information, please visit INNOVAX's official website: https://www.xiameninnovax.com/, and follow us on LinkedIn (@Xiamen Innovax Biotech Co., Ltd.) and X (@Innovax).